Lineage Cell Therapeutics, Inc. (LCTX) Stock Price, Quote & News - Stock Analysis (2024)

Lineage to Present at 2024 BIO International Convention Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) Lineage Announces Changes to Board of Directors Lineage Announces Appointment of New Board Member Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023 References